 <h1>Clavulanate / ticarcillin Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Interactions</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to clavulanate / ticarcillin: intravenous powder for injection, intravenous solution</i></p><h3>Hematologic</h3><p>The risk of significant bleeding may be increased in patients over the age of 60 years, patients receiving cytotoxic chemotherapy, patients with preexisting thrombocytopenia, and azotemia, and patients undergoing surgical procedures.</p><p></p><p>Leukopenia has been reported in 23% of patients with liver disease receiving beta-lactam antibiotics.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated eosinophils, thrombocytosis</p><p><b>Very rare</b> (less than 0.01%): Hemolytic anemia</p><p><b>Frequency not reported</b>: Bleeding manifestations, immune hemolytic anemia, positive Coombs test</p><p><b>Postmarketing reports</b>: Thrombocytopenia, leukopenia, neutropenia, eosinophilia, decreased hemoglobin or hematocrit, prolonged prothrombin time and bleeding time<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT</p><p><b>Postmarketing reports</b>: Elevated AST, elevated ALT, elevated serum bilirubin, transient hepatitis, cholestatic jaundice<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Onset of pseudomembranous colitis symptoms has been reported during or after antibacterial therapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Nausea, diarrhea</p><p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea</p><p><b>Postmarketing reports</b>: Stomatitis, flatulence, nausea, vomiting and diarrhea, epigastric pain, pseudomembranous colitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Postmarketing reports</b>: Skin rash, pruritus, urticaria, bullous reactions (including erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site phlebitis</p><p><b>Frequency not reported</b>: Injection site erythema, injection site infiltration</p><p><b>Postmarketing reports</b>: Injection site pain, injection site burning, injection site swelling, injection site induration, thrombophlebitis with IV administration<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Postmarketing reports</b>: Headache, giddiness, neuromuscular hyperirritability, convulsive seizures, taste and smell disturbances<sup>[Ref]</sup></p><p>Convulsions have been reported rarely, particularly in patients with renal dysfunction or those using high doses.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity reactions (including skin rash, pruritus, urticaria, arthralgia, myalgia, drug fever, chills, chest discomfort, bronchospasm, wheezing, anaphylactic reactions, bullous reactions [including erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome])<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Elevated serum creatinine and/or BUN<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Arthralgia, myalgia</p><h3>Other</h3><p><b>Postmarketing reports</b>: Drug fever, chills, chest discomfort, decreased serum potassium</p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Bronchospasm, wheezing</p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypokalemia</p><p><b>Postmarketing reports</b>: Elevated serum alkaline phosphatase, elevated serum LDH, hypernatremia, decreased uric acid<sup>[Ref]</sup></p><p>Some studies have shown a correlation between the degree of hypokalemia and the dose of ticarcillin in addition to the serum BUN/creatinine ratio.  These findings suggest that dehydration and high doses may be risk factors for hypokalemia.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vaginal yeast infections</p><p><b>Postmarketing reports</b>: Hemorrhagic cystitis<sup>[Ref]</sup></p><p>An increased incidence of vaginal yeast infections has been associated with penicillins.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Hallucinations</p><p id="ref_1">1. Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987): 1242-8</p><p id="ref_2">2. Meylan PR, Calandra T, Casey PA, Glauser MP "Clinical experience with timentin in severe hospital infections." J Antimicrob Chemother 17 (1986): 127-39</p><p id="ref_3">3. Tehan S, Horobin J, Gordonsmith R, McLatchie GR "Ticarcillin plus clavulanic acid (timentin): further UK trial results." Br J Clin Pract 42 (1988): 8-16</p><p id="ref_4">4. Sanders CV, Marier RL, Aldridge KE, Derks FW, Martin DH "Safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women." Am J Med 79 (1985): 96-100</p><p id="ref_5">5. Croydon EA, Hermoso C "An evaluation of the safety and tolerance to timentin." J Antimicrob Chemother 17 (1986): 233-40</p><p id="ref_6">6. Mostow SR, O'Brien RF "Safety and effectiveness of ticarcillin plus clavulanate potassium in treatment of lower respiratory tract infections." Am J Med 79 (1985): 78-80</p><p id="ref_7">7. Stuart JJ "Ticarcillin-induced hemorrhage in a patient with thrombocytosis." South Med J 73 (1980): 1084-5</p><p id="ref_8">8. Gentry LO, Macko V, Lind R, Heilman A "Ticarcillin plus clavulanic acid (timentin) therapy for osteomyelitis." Am J Med 79 (1985): 116-21</p><p id="ref_9">9. Gastineau D, Spector R, Philips D "Severe neutropenia associated with ticarcillin therapy." Ann Intern Med 94 (1981): 711-2</p><p id="ref_10">10. "Product Information. Timentin (ticarcillin-clavulanate)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_11">11. Link AS, Jr "Efficacy and safety of ticarcillin plus clavulanic acid and piperacillin in patients with lower respiratory tract infections." Am J Med 79 (1985): 86-7</p><p id="ref_12">12. Schwigon CD, Hulla FW, Schulza B, Maslak A "Timentin in the treatment of nosocomial bronchopulmonary infections in intensive care units." J Antimicrob Chemother 17 (1986): 115-22</p><p id="ref_13">13. Ryan J, Dudley FJ "Cholestasis with ticarcillin-potassium clavulanate (timentin)." Med J Aust 156 (1992): 291</p><p id="ref_14">14. Westenfelder M, Pelz K, Hulla FW "Clinical evaluation of timentin in complicated urinary tract infections." J Antimicrob Chemother 17 (1986): 97-102</p><p id="ref_15">15. Shenep JL, Hughes WT, Roberson PK, et al "Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer." N Engl J Med 319 (1988): 1053-8</p><p id="ref_16">16. Sweet JM, Jones MP "Intrahepatic cholestasis due to ticarcillin-clavulanate." Am J Gastroenterol 90 (1995): 675-6</p><p id="ref_17">17. Ramakrishnan K,  Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42</p><p id="ref_18">18. Brown LA, Goldberg ND, Shearer WT "Long-term ticarcillin desensitization by the continuous oral administration of penicillin." J Allergy Clin Immunol 69 (1982): 51-4</p><p id="ref_19">19. Finch RA "Hypernatremia during lithium and ticarcillin therapy." South Med J 74 (1981): 376-7</p><p id="ref_20">20. Welter J, Wittman DH, Freitag V "Ticarcillin therapy of risk patients with infections due to pseudomonas aeruginosa." J Int Med Res 9 (1981): 44-51</p><p id="ref_21">21. Nanji AA, Lindsay J "Ticarcillin associated hypokalemia." Clin Biochem 15 (1982): 118-9</p><p id="ref_22">22. Ramirez-Ronda CH, Gutierrez J, Bermudez RH "Comparative effectiveness, safety and tolerance of mezlocillin and ticarcillin: a prospective randomized trial." J Antimicrob Chemother 9 (1982): 125-9</p><h2>More about clavulanate / ticarcillin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: beta-lactamase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Aspiration Pneumonia</li>
<li>Bacteremia</li>
<li>Bacterial Infection</li>
<li>Bone infection</li>
<li data-more-config-id="list-data-resources-conditions">... +13 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>